Main Article Content
Iron, Therapies, Hypertension, DFX, DFO, Beta-thalassemia
Thalassemia which is one of the most common severe genetic blood disorders can lead to different ocular involvements.
Objectives: The basic aim of the study is to compare the deferasirox and desferrioxamine as iron chelators in patients with beta-thalassemia major.
Material and methods: This retrospective observational study was conducted in the medicine department of Services Hospital, Lahore from April 2022 to March 2023. The study included a total of 220 patients diagnosed with beta-thalassemia major who were undergoing iron chelation therapy with either DFX or DFO during the study period. Demographic information, including age, gender, and ethnicity, was recorded for each patient. Clinical characteristics, such as the date of betathalassemia major diagnosis, transfusion history, serum ferritin levels, liver and cardiac function assessments, and the presence of comorbidities, were meticulously documented.
Results: Data was collected from 220 patients, with 120 (54.5%) receiving Deferasirox (DFX) and 100 (45.5%) receiving Desferrioxamine (DFO). The study population had a mean age of 28.5 years, with 120 (54.5%) males and 100 (45.5%) females. 75 (34.1%) of patients had comorbidities, including diabetes mellitus, hypertension, and hypothyroidism. The change in serum ferritin levels from baseline to the end of the study period was 1250 ng/mL in the DFX group and 1650 ng/mL in the DFO group (p-value: 0.032).
Conclusion: It is concluded that, both Deferasirox (DFX) and Desferrioxamine (DFO) are effective iron chelation therapies for patients with beta-thalassemia major. DFX demonstrated a significant reduction in serum ferritin levels compared to DFO, but both therapies had similar effects on liver iron concentration and cardiac iron load.
2. Al-Kuraishy, Hayder M., and Ali I. Al-Gareeb. "Comparison of Deferasirox and Deferoxamine Effects on Iron Overload and Immunological Changes in Patients with Blood Transfusion-dependent β-thalassemia." Asian Journal of Transfusion Science, vol. 11, no. 1, 2017, pp. 13-17, https://doi.org/10.4103/0973-6247.200768.
3. Rivella S. ß-thalassemias: Paradigmatic diseases for scientific discoveries and development of innovative therapies. Haematologica. 2015;100:418–30
4. Mehreen A, Bano S, Ujala B. Beta thalassemia major; comparison of deferasirox versus desferrioxamine as iron chelator in multitransfused patients. Professional Med J 2017;24(2):315-321. DOI: 10.17957/TPMJ/17.3678
5. Winichagoon P, Kumbunlue R, Sirankapracha P, Boonmongakol P, Fucharoen S. Discrimination of various thalassemia syndromes and iron deficiency and utilization of reticulocyte measurements in monitoring response to iron therapy. Blood Cells Mol Dis. 2015;54:336–41
6. Chang HH, Lu MY, Peng SS, Yang YL, Lin DT, Jou ST, et al. The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent ß-thalassemia in Taiwan. Ann Hematol. 2015;94:1945–52.
7. Vichinsky E, Torres M, Minniti CP, Barrette S, Habr D, Zhang Y, et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: Two-year results including pharmacokinetics and concomitant hydroxyurea. Am J Hematol. 2013;88:1068–73.
8. AHMED , A., KAMRAN, M., MUKHTAR, M., ALI , M., & UMAIR, M. (2023). COMPARISON OF DEFERASIROX AND DESFERRIOXAMINE AS IRON CHELATORS IN MULTI-TRANSFUSED PATIENTS OF Β-THALASSEMIA MAJOR. Biological and Clinical Sciences Research Journal, 2023(1), 270. https://doi.org/10.54112/bcsrj.v2023i1.270
9. Gomber, S., Jain, P., Sharma, S. et al. Comparative efficacy and safety of oral iron chelators and their novel combination in children with thalassemia. Indian Pediatr 53, 207–210 (2016). https://doi.org/10.1007/s13312-016-0821-4
10. Rao, M. N., & Sana, S. (2022). COMPARATIVE EFFICACY AND SAFETY OF ORAL IRON CHELATORS AND THEIR NOVEL COMBINATION IN CHILDREN WITH THALASSEMIA. Int J Acad Med Pharm, 4(5), 40-47.
11. Tripathy, I., Panja, A., Dolai, T. K., & Mallick, A. K. (2021). Comparative Efficacy and Safety Between Deferiprone and Deferasirox with Special Reference to Serum Ferritin Level and Cardiac Function in Bengali β-Thalassemia Major Children. Hemoglobin, 45(5), 296-302.
12. BATOOL, T., AMIN, M. R. U., IQBAL, M., MALIK, F., KHAN, I., & YOUNAS, N. S. (2021). Evaluation of serum ferritin levels in children of South Punjab (Pakistan) having beta-thalassemia major with iron-overload treated with Deferasirox. Age (years), 10(29), 72-5.
13. Karunaratna, A. M. D. S., Ranasingha, J. S., & Mudiyanse, R. M. (2017). Iron overload in beta thalassemia major patients. Int J Blood Transfus Immunohematol, 7, 33-40.
14. Fibach, E., & Rachmilewitz, E. A. (2017). Iron overload in hematological disorders. La Presse Médicale, 46(12), e296-e305.
15. MOHAMED, O. H., MOHAMED, H. M., & ALI, A. (2022). Iron Chelation Therapy in Beta Thalassemia. The Medical Journal of Cairo University, 90(3), 633-639.
16. Kontoghiorghes, G. J. (2022). New Iron Metabolic Pathways and Chelation Targeting Strategies Affecting the Treatment of All Types and Stages of Cancer. International Journal of Molecular Sciences, 23(22), 13990.
17. Kontoghiorghes, G. J. (2022). New Iron Metabolic Pathways and Chelation Targeting Strategies Affecting the Treatment of All Types and Stages of Cancer. International Journal of Molecular Sciences, 23(22), 13990.
18. Porter, J. B., de Witte, T., Cappellini, M. D., & Gattermann, N. (2016). New insights into transfusion-related iron toxicity: Implications for the oncologist. Critical reviews in oncology/hematology, 99, 261-271.
19. Asees, M., Seir, R. A., Najjar, L., Najjar, O., Karmi, B., Shwekei, O., ... & Shamasna, W. (2019). PB2407 MANAGEMENT OF β-THALASSEMIA IN THE WEST BANK: IRON OVERLOAD AND AUTOANTIBODIES-A CROSS-SECTIONAL STUDY. HemaSphere, 3(S1), 1069-1070.
20. Saleem, A., Waqar, E., Shuja, S. H., Naeem, U., Moeed, A., Rais, H., & Ahmed, J. (2023). No difference in myocardial iron concentration and serum ferritin with deferasirox and deferiprone in pediatric patients with hemoglobinopathies: A systematic review and meta-analysis. Transfusion Clinique et Biologique, 30(1), 69-74.
21. Semra, K. O. C. A. (2021). Ganglion cell complex analysis in thalassemia major patients measured by optical coherence tomography. Health Sciences Quarterly, 1(2), 63-68.
22. Kolnagou, A., & Kontoghiorghes, G. J. (2018). Chelation protocols for the elimination and prevention of iron overload in thalassaemia. Frontiers in Bioscience-Landmark, 23(6), 1082-1098.
23. Sidhu, S., Kakkar, S., Dewan, P., Bansal, N., & Sobti, P. C. (2021). Adherence to iron chelation therapy and its determinants. International Journal of Hematology-Oncology and Stem Cell Research, 15(1), 27.
24. Haghpanah, S., Zekavat, O. R., Bordbar, M., Karimi, M., Zareifar, S., Safaei, S., ... & Ashraf, H. (2020). Ocular findings in patients with transfusion-dependent β-thalassemia in southern Iran. BMC ophthalmology, 20, 1-7.
25. Özbolat, G., & Yegani, A. A. (2021). Effects of curcumin on iron overload in rats. Sudan Journal of Medical Sciences, 16(4), 464-475.